Sunandana Chandra, MD, MS: Let’s switch gears and talk about the treatment modality of tumor-directed oncolytic therapies. These are intralesional therapies that many medical oncologists often employ in our practices. Dr Khushalani, when do you consider usage of this particular treatment modality for your patients?
2023
Pierce Underscores the Importance of 2-Step Verification With Relatlimab/Nivolumab
On this episode of The Vitals, Oncology Nursing News® talks with Amber Pierce RN, BSN, OCN, regional nurse manager at Oncology Hematology Associates, an American Oncology Network partner practice, about the importance of 2-step verification with nivolumab and relatlimab-rmbw (Opdualag), which was approved for patients with unresectable or metastatic melanoma in March 2022.
Free toolkit for clubs to keep members safe in the sun
With the weather warming up, and the Met Office predicting another summer of high temperatures, it’s important to factor in sun protection within your health and safety advice, specifically to those who spend prolonged periods outdoors.
The Complexities and Art of Interpreting Biomarkers and Response to Immune Checkpoint Inhibitors
A function of immune checkpoint inhibitors, such as PD-1 and PD-L1 inhibitors, is to allow normal tissues to coexist with the immune system and avoid triggering a destructive response.